FLUTAPHARM® IN COMBINED TREATMENT OF PROSTATE CANCER

Grygorenko V.M., Reznikov O.G., Chaykovs’ka L.V.

The paper reports findings dealing with the efficacy of, and tolerance to, the first domesticgenetically selective non-steroid antiandrogen — Flutapharm® — applied solely and as part of combined treatment in patients with Т1-4N0-1M1 prostate cancer. The drug investigated was shown to be well tolerated by patients and to cause no serious side effects requiring treatment discontinuation or application of any additional medication. Comparison with a reference drug (flucinom) did not reveal any considerable difference in terms of efficacy and tolerance. A combined НЕАТ scheme where Flutapharm® (250 mg three times a day) was administered in combination with sub- therapeutic doses of chlortrianizen (0.006 mg twice a day, sublingually) showed that the combined treatment was more efficient compared to monotreatment.